Moreover, expanded tumor-reactive TILs are often PD1-positive; therefore, preventing the interaction between PD1 on T cells and PDL1 on tumor cells through anti-PD1 therapy during TIL infusion may render the TILs more tumoricidal [53]. The gene discussed is CD274; the disease is neoplasm.